In section Market Quotes

ConvaTec Jumps 9.2% as It Raises 2026 Growth Forecast

ConvaTec shares rose 9.2% to 269.60 pence on Wednesday morning after the medical products company lifted its 2026 revenue growth forecast, citing faster growth in the second half. The stock led the FTSE 100, which was down 0.2%.

ConvaTec Jumps 9.2% as It Raises 2026 Growth Forecast

ConvaTec now expects 2026 organic revenue growth, excluding InnovaMatrix, of 6.25% to 7.0%, compared with its previous forecast of 5.5% to 6.5%. Organic revenue on the same basis increased 6.6% in the 10 months through October. Reported revenue growth was 4.8%, and total organic growth was 3.7%.

The company said growth strengthened in the second half in its infusion care and continence care businesses. “Revenue growth has accelerated in the second half, as we expected...Overall, we continued to gain share in all categories, underpinned by new product launches,” Chief Executive Officer Jonny Mason said.

ConvaTec kept its 2026 guidance for an adjusted operating profit margin of at least 23% and double-digit growth in adjusted earnings per share. It also reiterated medium-term targets for organic revenue growth of 6% to 8%, driving a double-digit increase in adjusted EPS.

J.P. Morgan analysts said concerns had persisted about the second-half growth step-up needed to meet 2026 guidance. The upgraded revenue forecast and unchanged margin guidance “should put those worries at ease,” they said.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!